Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Share News (EVG)

  • There is currently no data for EVG

Ebullient Evolution

Thu, 29th Oct 2009 08:23
Investment management firm Evolution Group expects to beat full year profit forecasts this year on the back of strong trading across all of its divisions.Revenues from the Investment Banking arm in the second half of 2009 will be at least double those seen in the first half, reflecting the increased corporate activity.The company is responding to this increased activity by boosting the division's headcount by around 10% in the second half of the year.On the Private Client Investment Management side, profits continue to pile up, while funds under management hit a record level of £5bn at the end of September, up from £4.2bn at the end of June. Net fund inflows exceeded £100m in the third quarter.'Given the successful results to date from investments made over the last 12 months and our growing business pipeline, the group is highly confident that it can continue the momentum in profit growth into 2010 and beyond,' the company said.

Related News

TRADING UPDATES: Norcros sells Johnson Tiles UK; Trifast trading well
25 Apr 2024

TRADING UPDATES: Norcros sells Johnson Tiles UK; Trifast trading well

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

TRADING UPDATES: Northcoders launches bootcamp; Schroder invests
4 Apr 2024

TRADING UPDATES: Northcoders launches bootcamp; Schroder invests

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

EARNINGS AND TRADING: Ten Lifestyle sees profit up but sales flat
19 Mar 2024

EARNINGS AND TRADING: Ten Lifestyle sees profit up but sales flat

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reporte...

EVG.L News

Evgen agrees fresh licensing deal with Spanish institutions
18 Jan 2022

Evgen agrees fresh licensing deal with Spanish institutions

(Sharecast News) - Clinical-stage drug development company Evgen Pharma announced a memorandum of understanding with the University of Seville, Consej...

Evgen signs agreement for Spanish institutions' sulfoaphane analogues
18 Jan 2022

Evgen signs agreement for Spanish institutions' sulfoaphane analogues

Evgen signs agreement for Spanish institutions' sulfoaphane analogues

EARNINGS UPDATES: Carr's beats expectations; Premier assets hit record
7 Dec 2021

EARNINGS UPDATES: Carr's beats expectations; Premier assets hit record

EARNINGS UPDATES: Carr's beats expectations; Premier assets hit record

UK earnings, trading statements calendar - next 7 days
30 Nov 2021

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

TRADING UPDATES: Permanent TSB sells loan portfolio; Dekel output up
10 Nov 2021

TRADING UPDATES: Permanent TSB sells loan portfolio; Dekel output up

TRADING UPDATES: Permanent TSB sells loan portfolio; Dekel output up

IN BRIEF: Evgen Pharma's SFX-01 effective on tumour cells
20 Sep 2021

IN BRIEF: Evgen Pharma's SFX-01 effective on tumour cells

IN BRIEF: Evgen Pharma's SFX-01 effective on tumour cells

IN BRIEF: Evgen SFX-01 granted orphan drug designation by US FDA
2 Sep 2021

IN BRIEF: Evgen SFX-01 granted orphan drug designation by US FDA

IN BRIEF: Evgen SFX-01 granted orphan drug designation by US FDA

Evgen pleased with preclinical data on SFX-01
13 Jul 2021

Evgen pleased with preclinical data on SFX-01

(Sharecast News) - Clinical-stage drug development company Evgen Pharma announced preclinical data demonstrating that 'SFX-01' was effective in in-vit...